How long can I take Lazertinib? Is there any risk of drug resistance?

Lazertinib (Lazertinib) is a third-generation EGFR tyrosine kinase inhibitor (TKI), mainly used to treat E Patients with GFRmutation-positive non-small cell lung cancer (NSCLC) have shown good efficacy in treatment regimens, especially after the emergence of T790M drug-resistant mutations. As a targeted drug, the duration of taking lanzetinib is usually determined by the maintenance of efficacy, the rate of disease progression, and the patient's individual tolerance.

In most clinical practices, as long as the patient's response to lanzitinib is stable, there are no serious side effects, and the disease has not progressed, the drug can be continued to be taken for up to several months or even years. Multiple clinical studies have confirmed that lanzitinib has a longer progression-free survival (PFS), and some patients can even maintain stable disease for more than one year after taking the drug, which also makes it an important choice for second-line or even first-line treatment of patients with EGFR mutations.

However, similar to other targeted drugs, long-term use of lanzitinib also carries the risk of developing drug resistance. Cancer cells in patients may gradually develop new mutations or activate other signaling pathways, thereby bypassing the inhibitory effect of EGFR. Common resistance mechanisms include C797S mutation, MET amplification, etc. Once resistance occurs, the therapeutic effect of Lanzertinib will gradually weaken or even become ineffective.

Therefore, while taking Lanzertinib, patients need to undergo regular reexamination, including imaging examinations and molecular genetic testing, to promptly evaluate efficacy and possible drug resistance trends. If resistance or reduced efficacy is found, doctors may consider switching to other targeted drugs or combination treatment strategies. In general, lanzetinib can be taken for a long time during its validity period, but the development of the disease should be closely monitored to deal with the potential risk of drug resistance.

Reference materials:https://www.drugs.com